Since its emergence in 2009, Candida auris has steadily become one of the most formidable threats haunting American hospitals and long-term care facilities. This multidrug-resistant yeast, once an obscure curiosity, now claims roughly 3,000 lives each year in the United States alone, according to data cited by Science and TechTimes. The Centers for Disease Control and Prevention (CDC) reported 3,437 confirmed clinical cases across 27 states by late July 2026—a number that, if trends hold, could surpass 7,000 by year’s end. But what makes C. auris so persistent, so difficult to eradicate, and so uniquely adapted to the modern healthcare environment?
A landmark study published in Science on August 6, 2026, by researchers at the University of California, San Francisco (UCSF), finally offers answers. The research team, led by Dr. Dean Merrill and Dr. Suzanne Noble, revealed that C. auris doesn’t just survive on the skin—it actively rewires the body’s immune response, turning hair follicles into sanctuaries where no current therapy can reach it. As Dr. Merrill put it to Science, “Candida auris colonizes skin way better than most other fungi, setting it up to invade once the immune system is weakened. The big clinical problem is that we have no effective way to remove it from the skin.”
The UCSF team compared C. auris with its more common cousin, Candida albicans, using advanced mouse models, single-cell RNA sequencing, and high-resolution microscopy. The results were striking: while C. albicans vanished from mouse skin within days, C. auris lingered, burrowing deep into hair follicles. This difference came down to a clever molecular maneuver. When exposed to the skin’s chemical environment, C. auris remodels its cell wall to expose more chitin—a tough polysaccharide found throughout nature. This chitin exposure triggers the body to release interferon-gamma (IFNγ), an immune signal usually reserved for viral threats. IFNγ, in turn, tells skin cells to dial down their antifungal defenses, especially those driven by interleukin-17A (IL-17A)—the very pathway that would normally clear a fungal invader.
“Chitin is widespread in nature, so it’s not like the human skin never encounters it, but we were surprised to see that C. auris actively uses its chitin to turn the skin into a perfect nest,” Dr. Noble explained to Science. The upshot is a skin environment reprogrammed by the fungus itself, with hair follicles becoming a long-term hideout where C. auris can persist for months—or indefinitely. No currently approved topical treatment can reach it there, and standard decolonization efforts have repeatedly failed.
The practical consequences for hospitals are stark. Patients colonized by C. auris—even those without symptoms—carry the fungus from ward to ward, or facility to facility, creating a persistent reservoir. Genomic studies, including a 2025 whole-genome sequencing survey of 494 isolates from Chicago, confirm that patient transfers, not environmental acquisition, drive most new introductions. This explains why the CDC, along with state health departments in Virginia, Indiana, Kansas, and Washington, now recommend a standardized infection control transfer form for all patient moves involving known or suspected C. auris cases.
But the skin isn’t the only battleground. C. auris is notorious for forming biofilms—dense communities of fungal cells encased in a β-glucan matrix—on hospital surfaces like bedrails, catheters, and doorknobs. According to TechTimes, the disinfectants most hospitals rely on—quaternary ammonium compounds (QACs)—are largely ineffective against these biofilms. Only products listed on the Environmental Protection Agency’s List P, containing active ingredients like hydrogen peroxide, peracetic acid, dodecylbenzenesulfonic acid (DDBSA), or sodium hypochlorite, have proven effective. Yet, as experts caution, even within this registry, not all products are validated for biofilm eradication, and staff under pressure may not always check the fine print.
Accurate diagnosis is another hurdle. Many community hospitals and skilled nursing facilities use outdated laboratory methods that can’t reliably distinguish C. auris from related species. The gold standard, updated MALDI-TOF mass spectrometry, is not yet universal. As Dr. Peter Chin-Hong of UCSF told Healthline, “Medical facilities should also invest in labs that can rapidly identify Candida auris, as it can be misidentified by older methods.” Without proper identification, patients may receive ineffective treatments and isolation protocols may not be triggered.
Who is at risk? The general public faces little threat—C. auris does not spread easily outside healthcare settings. The real danger is concentrated among those already medically vulnerable: patients on ventilators, central lines, catheters, or feeding tubes, and those with diabetes, blood cancers, or severe immune compromise. CDC data show that 88% of clinical cases between 2022 and 2024 occurred in adults aged 45 and older, mostly men, and mostly in acute care settings. The mortality rate for active infections is often cited at 30% to 60%, but most victims are already critically ill from other causes, making it hard to parse the fungus’s exact contribution.
Why did C. auris emerge as a human pathogen in the first place? Historically, mammals have enjoyed a natural protection: our body temperature (around 37°C) is too high for most soil fungi to thrive. But as Dr. Arturo Casadevall and colleagues at Johns Hopkins have argued in mBio and other journals, global warming is eroding this so-called “thermal barrier.” C. auris can now grow at temperatures up to 42°C—higher than human body temperature and well above its closest relatives’ limits. Genetic studies show that C. auris emerged independently in at least five clades across three continents, a pattern consistent with climate-driven selection rather than a single geographic origin. Environmental isolates from the Andaman Islands, for example, grow more slowly at 37°C than clinical strains, suggesting a recent adaptation to mammalian hosts.
So what can be done? For now, first-line treatment for active C. auris infections remains the echinocandin class of antifungals—caspofungin, micafungin, anidulafungin, and the newly approved rezafungin. Yet about 1% of strains are now resistant even to these, and pan-resistant cases (resistant to all three major drug classes) are rising. There is no approved cure for pan-resistant infections.
The UCSF study’s authors highlight two promising avenues: drugs that redirect the immune response from IFNγ back to IL-17, restoring the skin’s natural antifungal defenses, and drugs that block chitin recognition, preventing the IFNγ cascade from starting. Neither exists yet, but for the first time, researchers have a clear molecular target.
Meanwhile, the CDC stresses that prevention is paramount. Facilities must use private rooms, enforce strict isolation, and disinfect with EPA List P products. Updated diagnostics and coordinated transfer protocols are vital. As Dr. Graham Snyder of the University of Pittsburgh Medical Center told CNN, “We quickly learned that Candida auris is very good at sticking around in the environment—so we pay extra special attention when we know somebody has Candida auris to making sure that we clean and disinfect the environment.”
The story of C. auris is still unfolding, but the latest research makes one thing clear: as the world warms and pathogens adapt, healthcare’s battle against invisible invaders is only just beginning.